NCI-COG Pediatric MATCH

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

What's the purpose of the trial?

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
2316
Last Updated
2 months ago
Am I Eligible

Participating Centers

There are 160 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Ensartinib
  • Erdafitinib is a small molecule FGFR inhibitor that can work by slowing cancer cell growth and reproduction.
  • Larotrectinib is a first generation tropomyosin kinase (TRK) inhibitor used in the treatment of cancers that have TRK fusions.
  • Olaparib
  • Palbociclib is an oral drug that inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), blocking retinoblastoma (Rb) protein phosphorylation that leads to cell cycle arrest and cancer cell death.
  • Samotolisib is a PI3K/mTOR inhibitor that may help to slow the growth of and kill some types of cancer cells.
  • Samotolisib
  • Selpercatinib is a targeted therapy used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rearrangements.
  • Selumetinib is a MEK 1/2 inhibitor used in pediatric patients.
  • Selumetinib Sulfate
  • Tazemetostat is an EZH2 inhibitor that helps stop the spread of cancer cells.
  • Tipifarnib
  • Ulixertinib
  • Vemurafenib is a BRAF kinase inhibitor that is commonly used in the treatment of certain kinds of melanoma.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(831) 888-0898

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.